Freedom Capital analyst Ilya Zubkov downgraded Eli Lilly (LLY) to Hold from Buy with a price target of $950, up from $750. Eli Lilly delivered “one of the strongest quarters in its history,” says the analyst, who notes that strong performance and upward revisions to guidance have prompted the firm to raise revenue estimates. However, the firm is downgrading its rating due to current valuation levels.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- MeiraGTx enters strategic collaboration with Eli Lilly
- Novo Nordisk Stock (NVO) Rises on Plan to Pursue Other Obesity Deals after Metsera Loss
- Eli Lilly upgraded to Outperform from Market Perform at Leerink
- SanegeneBio announces RNAi licensing, collaboration with Lilly
- Pfizer Clinches $10 Billion Metsera Deal as Novo Nordisk Loses Weight-Loss Drug Battle